White House Withdraws FDA Nominee Overton Before Senate Vote
“The Administration withdrew Dr. Overton rather than make such commitments,” Senator Bill Cassidy wrote, according to Techdirt, as the Trump administration pulled its controversial pick to lead the Food and Drug Administration before a Senate panel vote on Wednesday.
The Tech TL;DR:
- The White House withdrew Dr. Heidi Overton’s FDA commissioner nomination on November 18, 2026, citing a lack of guaranteed votes in the Senate health committee.
- Acting Commissioner Kyle Diamantas approaches the 210-day limit under the Federal Vacancies Reform Act after taking over in May 2025.
- Public health advocates and anti-abortion groups both opposed the nomination over management concerns, vaccine policies, and drug access positions.
Senate committee vote called off
Dr. Heidi Overton was a top White House policy aide when President Trump tapped her for the role last summer, NPR reported. The Senate Health Committee questioned her during a September hearing, but the panel delayed any decision until the scheduled November vote, according to NPR.
Cassidy, a Louisiana Republican who chairs the health committee, stated on CBS’s “Face The Nation” on Sunday that he remained undecided. His committee held only a one-vote majority, meaning a single defecting Republican could sink the nomination if all Democrats voted against it, Techdirt reported.
Cassidy maintained he had productive conversations with committee members and believed Overton would have cleared his committee. He asserted that anti-abortion senators seeking assurances about the administration’s commitment to life issues caused the final hangup, according to Techdirt.
The White House said Tuesday it has pulled the nomination of Dr. Heidi Overton to lead the Food and Drug Administration amid growing indications she didn't have the votes needed to win Senate confirmation. https://t.co/nus5y4MTsR
“My conversations with her convinced me she would follow the science and push back against decisions that put Americans’ health at risk,” Cassidy wrote, as cited by Techdirt.
Abortion policies and MAHA friction
That rationale drew skepticism because Overton celebrated the overturning of Roe v. Wade and refused to admit during confirmation hearings that mifepristone is medically safe, Techdirt reported. An anti-abortion group, Susan B. Anthony Pro-Life America, urged lawmakers to delay the vote until the administration eliminates mail-order access to the abortion pill, NPR noted.
Former Kennedy senior adviser Calley Means alleged this month that Overton wrote a policy relaxing standards for fruit-flavored vapes. Means also claimed she helped the Justice Department construct a legal argument to shield major chemical company Bayer from lawsuits connected to its pesticide products, according to Techdirt.
“She was one of the chief architects,” Dr. Rob Davidson said of Overton’s role in public health policy, according to NPR. Davidson serves as an emergency room physician and executive director of the Committee to Protect Healthcare.
The White House has pulled Dr. Heidi Overton's nomination to lead the FDA in the face of Senate opposition to her candidacy, according to a White House official and two sources familiar with the matter. https://t.co/oxIzXrOSSi pic.twitter.com/6otiBsnX9y
Davidson said that Overton shares blame for the current measles outbreak. He told NPR she stood by Trump in August when he signed an executive order changing the childhood vaccine schedule and questioning MMR vaccine safety.
Dr. Robert Steinbrook, health research group director at Public Citizen, also opposed the confirmation. Steinbrook told NPR that her lack of managerial experience alone should be disqualifying for an agency with 18,000 employees regulating food, medicines, medical devices, and tobacco.
Acting commissioner limit approaches
Kyle Diamantas has served as Acting Commissioner since May. The Federal Vacancies Reform Act limits an acting commissioner to 210 days, placing Diamantas just shy of 200 days in the role, Techdirt reported. The agency has lacked a confirmed commissioner since Dr. Marty Makary resigned in May following a tumultuous 13-month tenure, according to NPR.
Dr. Heidi Overton, born in 1989 in Cortez, Colorado, graduated summa cum laude from the University of New Mexico in 2011 and earned her medical degree there in 2015. She served as the university’s student regent, confirmed by the New Mexico Senate, and completed residency training at Johns Hopkins Hospital, where she studied opioid guidelines with Marty Makary and earned a doctorate in clinical investigation in 2022.
Overton was named a White House fellow in December 2019, working on the COVID-19 response. After the 2020 election, she directed the Center for a Healthy America at the America First Policy Institute.
Following Trump’s 2024 victory, she became deputy assistant to the president for domestic policy, helping hire Robert F. Kennedy Jr.’s staff and mediating between Kennedy and Agriculture Secretary Brooke Rollins on the MAHA Commission before her FDA nomination in August 2026.
Cassidy said that confirming a permanent FDA commissioner will now fall to Senate Democrats given the limited time left in the congressional session, Techdirt reported.
Breaking news: The White House is abandoning the nomination of Heidi Overton to lead the FDA amid growing concerns that she could not be confirmed by the Senate. https://t.co/JWHZ1WjVpd
More on White House
The White House has pulled Dr. Heidi Overton's nomination to lead the FDA in the face of Senate opposition to her candidacy, a White House official confirmed. https://t.co/1bGWGjEke1
Dr. Heidi Overton’s nomination to lead the Food and Drug Administration was dropped on Tuesday, a White House official confirmed to ABC News. Read more: https://t.co/oobI2rEEGl pic.twitter.com/YPSdHLwlNO